Gosset Ownership
Private
Employees
~50
Therapeutic Areas
Stage
Phase 2
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Asterias Biotherapeutics General Information
Asterias was conducting Phase 1/2a clinical trials for AST-OPC1 in spinal cord injury and VAC2 in non-small cell lung cancer. The company merged with BioTime in a transaction that was expected to be completed in Q1 2019.
Contact Information
Primary Industry
Biotech
Corporate Office
Menlo Park, California
United States
United States
Drug Pipeline
OPC1
Phase 2Key Partnerships
California Institute for Regenerative Medicine (CIRM), Cancer Research UK, Wuchan Zhongda Geron
Asterias Biotherapeutics Funding
No funding data available
To view Asterias Biotherapeutics's complete valuation and funding history, request access »